Adlens, the global leader in adjustable focus eyewear, has launched its ground-breaking adjustable prescription eyewear ‘AdlensFocuss™’, the greatest advancement in optics in more than 50 years.
Vision inevitably changes with age and people often need different strength glasses to see at near, intermediate and far distances. Progressive lenses are an option but they have a restricted usable lens area. A GFK Roper Study has shown one-third of wearers say they have trouble adjusting to them with seven to eight percent of wearers saying they cannot adjust to them at all.
AdlensFocuss provides the benefits of a single vision lens – full frame viewing area – with the best features of a progressive lens – the ability to see at different distances. They are prescription glasses with proprietary technology; a unique flexible membrane that allows the power to be adjusted by simply turning small dials on the inside of the frames. AdlensFocuss lenses offer at least four times more viewing area than traditional progressive lenses and come encased in a fashion-forward frame from award-winning designer Blake Kuwahara.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7544851-adlensfocuss-optics-technology/
ACCU-CHEK Aviva Expert offers people with diabetes a new and easy way to simplify complex calculations to deliver precise insulin dosing advice.
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the ACCU-CHEK® Aviva Expert system, the first and only blood glucose meter system with a built-in insulin calculator to be approved by the U.S. Food and Drug Administration (FDA), is now available by prescription. The device represents a significant advancement in blood glucose meter technology for people with diabetes who take multiple daily insulin injections. The meter’s integrated bolus calculator provides easy-to-use and reliable dose recommendations based on automated calculations, eliminating the need for manual dosing calculations and estimations.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7322751-roche-accu-chek-aviva-expert-blood-glucose-meter-now-available/
Turning your clocks ahead an hour on March 8 for the start of Daylight Savings Time may be known as the unofficial start to spring, but for many, it’s known as the day we lose an hour of sleep. As you prepare to change your clocks on Sunday, take that opportunity to evaluate your sleeping habits. The loss of that hour of sleep can turn minor sleep issues into major ones.
“When we move our clock forward or backward, our internal clock becomes out of sync with the external time,” says Dr. Daniel Shade, Board Certified Sleep Specialist and Director of the AHN Sleep Disorders Center. “The best way to combat this is to expose ourselves to light and let our bodies resynchronize.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7447951-remworks-daylight-savings-sleep-coach/
Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) launched Access Better Coverage.org, a new website designed to educate consumers about the ABCs of health coverage and access to prescription medicines.
The new site introduces important resources to help people better understand how health insurance works and what to expect from their coverage, including a series of white board videos explaining basic insurance terms like deductibles, copays and coinsurance, and how formularies and tiers work.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7350551-phrma-health-insurance-access-better-coverage/
Eyeglass World®, a leading retailer of affordable prescription eyewear, is the first national chain to launch a retail collection of prescription lenses for smart glass technologies in the U.S. The debut of specially designed prescription lens options for wearable brands including Glass, Recon, Vuzix and Epson coincides with Eyeglass World’s retail expansion into California. On Friday, the company celebrated the grand opening of a Vista, California location – the first of eight Eyeglass World stores planned for the San Diego area by June 2016.
To view the Multimedia News Release, go http://www.multivu.com/players/English/7544551-eyeglass-world-expands-debuts-smart-glass/
Meijer announced today it is launching its new Consumer Drug Take-Back Program by installing secure in-store kiosks designed to help customers safely and properly dispose of unused or expired prescription drugs at no cost. Customers can find the easily identifiable kiosks in the pharmacy area in all 241 Meijer supercenters across the Midwest.
“Meijer is thrilled to be one of the first in our industry to provide a secure and convenient prescription drug take-back program at all stores in the communities we serve,” said Jason Beauch, Vice President of Meijer Pharmacy. “The Meijer Drug Take-Back Program allows our customers to remove the risk of an unforeseen accident occurring with expired or unused medications, while enabling them to properly dispose prescription drugs and reducing the possibility of creating a public health hazard.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8497051-meijer-consumer-drug-take-back-program/
Millennium Health, a leading health solutions company, today announced the launch of the Drop Them Off campaign, in partnership with the Mark Wahlberg Youth Foundation and the Partnership for Drug-Free Kids’ Medicine Abuse Project. Designed to increase awareness of the problem of youth misuse and abuse of prescription medicine, the campaign intends to educate parents and youth on how to properly use, store, and dispose of prescription medications by dropping them off at appropriate collection sites among other methods, to reduce access and opportunity for misuse or abuse. Educational content will be available online (www.DropThemOff.com) and through curriculum delivered through the Mark Wahlberg Youth Foundation’s community-based partners. Millennium Health is a Silver Sponsor of the Medicine Abuse Project, a campaign that aims to prevent half a million teens from abusing medicine by 2017.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7071752-millennium-health-drop-them-off/
There is only one choice when it come to nutrition that slows down kidney disease and helps joint problems at the same time - The Hill's Science Diet K/D + Mobility.
Learn more here: https://tier1petproducts.com/best-dog-food-for-kidney-disease/
Chronic kidney disease (CKD) is a condition often associated with advanced age. According to recent data 1 out of 10 dogs will develop CKD in his lifetime.
It is also common for senior dogs to develop other age-related conditions such as reduced mobility or cognitive dysfunction which can significantly impact the quality of life of both the pet and the pet parent.
Nutrition can play a key role in managing these age-related conditions. That is why Hill’s nutritionists and veterinarians developed new Prescription Diet K/D + Mobility for dogs.
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that many retina specialists throughout the U.S. are now using ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg to treat patients with diabetic macular edema (DME). The first injections of ILUVIEN in the U.S. were captured during a live web event attended by more than 250 eye care professionals. ILUVIEN is the first multiyear eye implant designed to deliver a continuous, submicrogram daily dose of steroid to the retina for 36 months with one injection. ILUVIEN is indicated for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP).
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7496251-iluvien-dme/
More than 15 percent of reproductive-aged women have filled a prescription for an antidepressant medication during the years 2008–2013, according to a new analysis published today in the Centers for Disease Control and Prevention (CDC)’s Morbidity and Mortality Weekly Report (MMWR).
January is National Birth Defects Prevention Month and the CDC is working with the March of Dimes to raise awareness about the use of antidepressant medications by women of reproductive age, and what women should know and do for their own health and that of their babies. There is conflicting evidence about the potential link between some antidepressants and certain birth defects. Some commonly used antidepressants are sertraline (Zoloft), bupropion (Wellbutrin, Zyban), and citalopram (Celexa).
To view the multimedia release go to:
http://www.multivu.com/players/English/7709851-march-of-dimes-antidepressant-pregnancy-study/
Eisai Inc. today announced the launch of a new national television advertising campaign for BELVIQ® (lorcaserin HCl) CIV, an FDA-approved prescription therapy for chronic weight management. The advertisement will air on numerous channels including Lifetime, Oxygen and AMC.
The spot illustrates the struggles many people face when they are trying to lose or control their weight. BELVIQ is presented as a targeted approach to weight loss, that, when combined with diet and increased activity, may help some patients lose weight and keep it off.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/7161051-eisai-launches-national-television-campaign-belviq-lorcaserin-hcl-civ
The following statement is being issued by Branstetter, Stranch & Jennings, PLLC regarding In re Prograf Antitrust Litigation.
A lawsuit is currently pending claiming that Astellas Pharma US, Inc. (“Astellas” or “Defendant”) violated state antitrust, unfair competition, consumer protection, and unjust enrichment laws of certain states by delaying the availability of a less expensive generic version of the immunosuppressant prescription drug Prograf® (known as tacrolimus). Plaintiffs allege that Defendant’s conduct caused some consumers and third party payors to pay too much for Prograf in certain states from September 3, 2008 to December 31, 2010 (also referred to as the “Class Damage Period”). This lawsuit does not claim that Prograf is unsafe or ineffective. Astellas denies any wrongdoing.
To view the multimedia release go to:
http://www.multivu.com/players/English/7933851-prograf-antitrust-class-action-settlement/
